Brain tumour clinical trial title

Diffusion Imaging in Gliomas (Study ID: 17622)

Brain tumour type




Glioblastomas are the most common and aggressive type adult brain cancers, and the commonest cause of cancer death in women under 35 and men under 45. Average survival is just over a year. Standard MRI scanning is not good at detecting how well the tumour responds to treatment early, and can sometimes be misleading; tumours may appear to grow when they are actually responding to treatment, and conversely appear to shrink when they are progressing. We therefore require better scanning methods to assess whether a particular treatment is working for an individual patient and for testing new anti-cancer drugs in trials. A specialised type of MRI scan called diffusion weighted imaging (DWI) allows the properties of water in the tumour and surrounding brain to be measured. DWI has been shown to detect a tumour responding to treatment much earlier than standard MRI, but has only been tested in single centres. The best way of acquiring and analysing DWI and comparing results from different MRI scanners for clinical use has not been established. This project aims to develop, test and refine diffusion MRI techniques as a method that can be used across multiple centres to measure tumour treatment response and growth into surrounding normal brain in patients with glioblastoma. Healthy volunteers will be recruited for scan development and comparison. 120 patients with newly diagnosed glioblastoma having standard treatment with surgery, radiotherapy and chemotherapy at specialist brain tumour centres will have standard and advanced MRI scans before and after treatment. Patients DWI data will be compared with their subsequent progress and survival, and the best DWI indicators selected. The intended impact is: • Improved personalised treatment decision making for individual patients. • More reliable early assessment of the effectiveness of new drugs and drug combinations in multi-centre trials, for improved future patient care. Research Summary

Date added: 11th January 2019

Open/Closed: Open

Trial ends: October 2021


Imperial College of Science, Technology and Medicine

Contact details

Ms Lesley Honeyfield :
South Kensington Campus


Find on Google maps »